stockrow
Monday 9 November 2026
Export BBOT’s income statement to Excel — free account
BridgeBio Oncology Therapeutics, Inc
BBOT- EPS
- −25.3%
- Free cash flow
- −88.8%
Quarter to June 2026, against a year earlier
2.04
0.13
−5.99%
Follow BBOT
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | (74) | (134) | (182) | +80.5% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | 0 | (74) | (134) | (182) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | (5,756.41) | (4.30) | (2.76) | (99.9%) | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (4,265.66) | (3.66) | (1.89) | (99.9%) | ||||||
| Capex | — | — | — | — | — | — | — | — | (3.80) | (0.02) | 0.00 | (99.5%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (4,269.46) | (3.68) | (1.89) | (99.9%) | ||||||
| Book value | — | — | — | — | — | — | — | — | (13,847.83) | 13.20 | 4.04 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 0 | 31 | 71 | +241,334.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (55) | (114) | (151) | +107.0% | |||||
| Capex | — | — | — | — | — | — | — | — | 0 | (1) | 0 | +1,136.7% | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (55) | (114) | (152) | +107.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 139 | 397 | 191 | +185.6% | |||||
| Net debt | — | — | — | — | — | — | — | — | (156) | (425) | (226) | +173.4% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (179) | 411 | 323 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | (90.41) | (43.76) | (96.69) | +46.7 pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | (127.66) | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | (115.33) | (252.10) | (115.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 92 | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | — | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
BridgeBio Oncology Therapeutics, Inc vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TRDA Entrada Therapeutics, Inc. | $191.5M | — (loss-making) | — (loss-making) | −43.93% (below 0%: shrinking) | n/m | −7.05% (below 0%: shrinking) | 100.00% | (4,606.52%) | Compare |
| CGEN Compugen Ltd. | $185.7M | 5.2× | — (loss-making) | +107.00% (above 0%: growing) | n/m | −155.42% (below 0%: shrinking) | (3.54%) | (339.62%) | Compare |
| MDWD MediWound Ltd. | $184.0M | — (loss-making) | — (loss-making) | −45.83% (below 0%: shrinking) | n/m | −49.90% (below 0%: shrinking) | 10.90% | (305.89%) | Compare |
| BCYC Bicycle Therapeutics PLC Sponsored ADR | $182.5M | — (loss-making) | — (loss-making) | +190.24% (above 0%: growing) | n/m | +43.48% (above 0%: growing) | 100.00% | (39.57%) | Compare |
| ACOG Alpha Cognition Inc. | $180.5M | — (loss-making) | — (loss-making) | +267.56% (above 0%: growing) | n/m | −109.25% (below 0%: shrinking) | 94.80% | (127.29%) | Compare |
| WHWK Whitehawk Therapeutics, Inc. | $178.4M | — (loss-making) | — (loss-making) | +33.48% (above 0%: growing) | n/m | +72.57% (above 0%: growing) | 89.36% | 0.00% | Compare |
| UPB Upstream Bio, Inc. | $176.9M | — (loss-making) | — (loss-making) | −17.50% (below 0%: shrinking) | n/m | +9.33% (above 0%: growing) | 100.00% | (5,480.98%) | Compare |
| IVVD Invivyd, Inc. | $166.0M | — (loss-making) | — (loss-making) | +21.20% (above 0%: growing) | n/m | −226.89% (below 0%: shrinking) | 91.09% | (320.76%) | Compare |
| BBOT BridgeBio Oncology Therapeutics, Inc | $163.6M | — (loss-making) | — | — | n/m | −88.78% (below 0%: shrinking) | — | 0.00% | |
| Median of peers | $181.5M | — | — | +27.34% | — | −28.47% | 92.95% | (313.32%) |
Pay and ownership Proxy statement filed 28 April 2026
Ownership
Directors and executive officers, together
24.40%
Bihua Chen, M.B.A.
22.30%
Certain investment vehicles managed by Cormorant Asset Management, LP
22.30%
BridgeBio Pharma LLC
18.30%
Entities affiliated with Deerfield Management Company, L.P.
6.10%
BC Global Opportunities IX LP
5.40%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement